Cargando…
Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
Mucopolysaccharidosis type IVA (MPS IVA) is an autosomal recessive lysosomal storage disorder caused by mutations in the GALNS gene, which leads to deficient activity of N‐acetylglucosamine‐6‐sulfate sulfatase. MPS IVA patients usually present skeletal dysplasia, coarse features, short stature, airw...
Autores principales: | Politei, Juan, Porras‐Hurtado, Gloria Liliana, Guelbert, Norberto, Fainboim, Alejandro, Horovitz, Dafne Dain Gandelman, Satizábal, José María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932870/ https://www.ncbi.nlm.nih.gov/pubmed/33728253 http://dx.doi.org/10.1002/jmd2.12192 |
Ejemplares similares
-
Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America
por: Solano, MarthaL., et al.
Publicado: (2020) -
Determination of genotypic and clinical characteristics of Colombian patients with mucopolysaccharidosis IVA
por: Tapiero-Rodriguez, Sandra M, et al.
Publicado: (2018) -
Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2018) -
Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013) -
Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
por: Ficicioglu, Can, et al.
Publicado: (2020)